Recent Activity

Loading...

ALPN

Alpine Immune Sciences, Inc. · NASDAQ

Performance

+0.51%

1W

+0.93%

1M

+123.03%

3M

+443.23%

6M

+240.87%

YTD

+649.37%

1Y

Profile

Alpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Investment Analysis Report: ALPN

Overview

ALPN is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $2.05 billion. In this report, we will conduct a comprehensive analysis of ALPN's financial statements over the past three years, including the balance sheet...

See more ...

Technical Analysis of ALPN 2024-05-10

Overview:

In analyzing the technical indicators for ALPN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions to guide investme...

See more ...

Recent News & Updates